Pharma

Taking stock of the drug industry, from the lab to the medicine chest

Pharmalot

Pharmalittle: Trump to require drug prices in ads; Europe cracks down on valsartan ingredients maker

By Ed Silverman

Diabetes Transplants
Pharmalot

Merck scraps plans to sell a biosimilar version of Lantus as the insulin market gets crowded

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: FDA approves a record number of generics; Bristol-Myers’ Opdivo fails lung cancer study goal

By Ed Silverman

Cancer Research Cells
Pharmalot

Industry influence over clinical trial design and reporting lacks transparency

By Ed Silverman

Pharmalot

Pfizer pays $700,000 to settle charges over misleading copay coupons

By Ed Silverman

Pharmalot

Pharmalittle: Azar promises more action on drug costs; Trump flubs explanation of ‘gag clause’ law

By Ed Silverman

Pill Dollars
Pharmalot

Surprise, surprise: Price hikes contributed a lot to sales growth for the biggest-selling drugs

By Ed Silverman

Utility pole
Pharmalot

A growing number of states consider legislation to treat pharma as a utility

By Ed Silverman

Pharmalot

Pharmalittle: Brexit fears hurt U.K. clinical trial work; Pfizer readies its new executive team

By Ed Silverman

Pharmalot
Pharmalot

McKesson failed to follow procedures when confronted with illegitimate products

By Ed Silverman

Pharmalot

Pharmalittle: Merck wins a VA contract for a biosimilar; after a decade, Reagan-Udall has little cash

By Ed Silverman

Pharmalot
Pharmalot

Ohio Medicaid examines a curious PBM relationship. Do other states have a similar issue?

By Ed Silverman

Vertex
Pharmalot

A Canadian advisory group says a Vertex cystic fibrosis drug isn’t worth covering

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Lilly trial results may spell trouble for Novo; Japan looks for ‘reasonable’ drug prices

By Ed Silverman

Opioid Lawyers
Pharmalot

Once again, a New Jersey court gives pharma a boost in lawsuits filed by consumers

By Ed Silverman

Pharmalot

Pharmalittle: PhRMA refiles suit against California transparency law; a shadowy new pharma group emerges

By Ed Silverman

Pills On Conveyor Belt
Pharma

Fast, nimble, and on demand: the pursuit of a new way to mass produce medicines

By Karen Weintraub

A photo of Hydrocodone Acetaminophen.
Pharmalot

The opioid litigation will take a long time to settle, but may cost less than the Big Tobacco deal

By Ed Silverman

Pharmalot

Pharmalittle: Sloan Kettering CEO resigns from Merck board; drug maker suspends U.K. trials over Brexit fears

By Ed Silverman

Gottlieb Generic Drugs
Pharmalot

FDA looks to block drug makers from using citizen petitions to delay generics

By Ed Silverman

GSK
Pharmalot

Glaxo ‘turns back the clock’ and resumes payments to doctors

By Ed Silverman

Cancer Chemotherapy
Pharmalot

Cancer trials that rely on surrogate endpoints overlook quality-of-life issues

By Ed Silverman

Pharmalot

Pharmalittle: Former Celgene exec gains ground in N.J. Senate race; NAFTA deal may cost patients

By Ed Silverman

AmerisourceBergen
Pharmalot

AmerisourceBergen pays $625 million to settle allegations of illegally distributing drugs

By Ed Silverman

Pharmalot

New U.S. trade deal with Canada and Mexico is criticized for provisions affecting drug prices

By Ed Silverman

Pharmalot

Pharmalittle: Pfizer CEO Ian Read to step aside; Novo Nordisk cutting 250 jobs in the U.S.

By Ed Silverman

An image of Ian Read.
Pharmalot

Pfizer CEO Ian Read to step aside and be replaced by veteran executive

By Ed Silverman

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy